Omics-based biomarkers for progression and therapy monitoring related to disease pathways
- Validate and optimize known biomarkers in 300 SPG patients
- Apply lipid biomarkers in 15 SPG5 patients as readouts in therapeutic trials
- Screen newly identified lipid biomarkers in SPG
- Validate and optimize known biomarkers in 100 SCA patients and persons at risk, as well as 220 HD patients
- Validate existing and screen newly identified biomarkers in more than 800 NMD patients